Loading
NASDAQHealthcareBiotechnology
Latest quote
$13.07
+$0.47 · +3.73%
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Latest quote
$13.07
+$0.47 · +3.73%
Regular session · ET · Market data may be delayed.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
43
Fair Value
Sentiment
74
Bullish
Risk
70
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 67.67M USD | 57.88M USD | 36.28M USD | 52.12M USD | 33.05M USD |
| Cost of goods sold | 15.92M USD | 10.29M USD | 8.98M USD | 7.57M USD | 6.89M USD |
| Gross profit | 51.75M USD | 47.59M USD | 27.3M USD | 44.55M USD | 26.16M USD |
| Research and development | 388.86M USD | 466.31M USD | 435.07M USD | 419.98M USD | 229.81M USD |
| Selling, general, and administrative | 119.8M USD | 125.83M USD | 116.5M USD | 90.31M USD | 71.1M USD |
| Operating expenses | 492.74M USD | 581.86M USD | 542.59M USD | 502.71M USD | 294.01M USD |
| Interest income | 29.2M USD | 47.81M USD | 49.83M USD | 8.54M USD | 1.28M USD |
| Depreciation and amortization | 15.92M USD | 10.29M USD | 8.98M USD | 7.57M USD | 6.89M USD |
| Operating income | −440.99M USD | −534.26M USD | −515.29M USD | −458.16M USD | −267.85M USD |
| Net income | −412.69M USD | −519.02M USD | −481.19M USD | −474.19M USD | −267.89M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK141.56M2.06%5.56B USD0.75%$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI56.03M0.55%9.87B USD0.35%$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI54.74M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM45.67M0.06%78.27B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB39.69M0.02%185.3B USD0.03%$289.48+0.64%
ARK Genomic Revolution ETFARKG37.83M1.85%1.56B USD0.75%$51.30+4.08%
Vanguard Morningstar Small-Cap Growth ETFVBK22.73M0.05%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF20.64M0.02%95.4B USD0.05%$235+0.80%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
